BK Technologies [BKTI] - Last Close: $11.52
BK Technologies is on a hot streak after a recent insider buy.
On August 17th, a Form 4 filing revealed CEO John Suzuki bought 4,228 shares of common stock at an average purchase price of $10.50 per share.
The news sparked a rally in shares of BKTI that lasted until Tuesday of this week, but shares have pulled back over the past two sessions.
However, it appears the pullback may have been overdone because BKTI is rebounding in today's premarket, despite no major news.
BKTI is one of this morning's top gainers with a 16.8% advance.
My Take: BKTI appears to be enjoying some short-term support from dedicated swing traders, but I think it will take more than an insider buy to lift share prices back to their 52-week high.
T2 Biosystems [TTOO] - Last Close: $0.3519
T2 Bio is rebounding after a steep sell-off.
The micro-float biotech announced plans for a public offering of 141 million shares of common stock early Thursday, and the market wasn't pleased.
Shares of TTOO fell 26.3% on the news as investors gauged the impact of potential dilution of shareholder value.
However, the declines didn't last long, and TTOO is recapturing a lot of its lost ground in today's premarket.
TTOO is up 20.8% on elevated premarket trading volume.
My Take: TTOO looks like a stinker. It had a good run earlier this month, but the rally quickly dissipated. I don't think these gains will last, either.
YS Biopharma [YS] - Last Close: $0.779
YS Bio is climbing after a late Thursday announcement.
After yesterday's close, the tiny biotech said its chairman and CEO had purchased upwards of 475,000 shares of common stock on the open market.
Founder & chairman Yi Zhang purchased 429,188 shares at an average cost of $1.407, while CEO Dr. Hui Shao bought 46,300 at $1.46 per share.
Combined, the total value of the insider buys adds up to more than $671,000.
YS is leading today's premarket movers with a 53.4% gain on elevated trading volume.
My Take: Not much to write home about with YS. Its chart is pretty ugly, and I don't think the insider buy will do much to improve its long-term trajectory.
